North Immunology is going public via a reverse merger with Aethlon Medical, raising $180 million to advance a long-acting, dual-acting immunology and inflammation program for atopic dermatitis. The transaction gives the company a financing runway while keeping focus on clinical evaluation of its eczema asset as the field intensifies around IL-4/IL-13 and broader immune-modulating approaches. The reverse merger approach reflects a market window in which at least some investors are willing to fund preclinical or early clinical risk through public-market vehicles rather than waiting for traditional IPO timing. For the startup ecosystem, it provides a faster path to liquidity and visibility as companies compete for attention in immunology. Other reporting tied North Immunology’s listing to broader reverse-merger sentiment and capital availability in 2026. For industry leaders, the move underscores how capital markets are increasingly accommodating platform-style bets in immunology when clinical differentiation claims are credible. North Immunology’s disclosed path is to bring its bispecific approach toward the clinic with the raised capital, aiming to establish efficacy and tolerability signals versus established biologics competitors.